HepaTx Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Crowdfunding
  • (Announced)

  • Latest Deal Amount
  • $1.24M

  • Investors
  • 15

HepaTx General Information

Description

Developer of a stem cell-based therapy designed to replace liver transplants as a treatment for liver failure. The company's therapies are based on the principles of regenerative medicine, which allow the patient's body to actively repair damaged tissues and organs, enabling physicians to easily help previously untreatable patients in a cost-effective way.

Contact Information

Website
www.hepatx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2627 Hanover Street
  • Palo Alto, CA 94304
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 2627 Hanover Street
  • Palo Alto, CA 94304
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HepaTx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Equity Crowdfunding 11-Sep-2026 $1.24M Announced Pre-Clinical Trials
10. Later Stage VC 12-Apr-2024 Completed Pre-Clinical Trials
9. Accelerator/Incubator 01-Mar-2024 Completed Pre-Clinical Trials
8. Angel (individual) 01-Nov-2022 Completed Pre-Clinical Trials
7. Secondary Transaction - Private Completed Pre-Clinical Trials
6. Seed Round 31-May-2021 Completed Pre-Clinical Trials
5. Seed Round 01-Apr-2019 Completed Product In Beta Test
4. Accelerator/Incubator 21-Aug-2018 Completed Product In Beta Test
3. Seed Round 01-Jul-2018 $3.5M $3.93M Completed Product In Beta Test
2. Accelerator/Incubator $427K Completed Product In Beta Test
To view HepaTx’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

HepaTx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a stem cell-based therapy designed to replace liver transplants as a treatment for liver failure. The compa
Drug Discovery
Palo Alto, CA
3 As of 2026

Mont-Saint-Guibert, Belgium
 

Pittsburgh, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HepaTx Competitors (3)

One of HepaTx’s 3 competitors is Cellaion, a Formerly VC-backed company based in Mont-Saint-Guibert, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cellaion Formerly VC-backed Mont-Saint-Guibert, Belgium
LyGenesis Venture Capital-Backed Pittsburgh, PA
Surrozen Formerly VC-backed South San Francisco, CA
You’re viewing 3 of 3 competitors. Get the full list »

HepaTx Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

HepaTx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250312382-A1 Cell therapy for treating liver disease Pending 04-Apr-2024
WO-2025212376-A1 Novel compositions for treating disease Pending 04-Apr-2024
US-20250102522-A1 Methods of tracking donor cells in a recipient Pending 07-Oct-2021
WO-2023060186-A1 Methods of tracking donor cells in a recipient Inactive 07-Oct-2021 G01N33/6893

HepaTx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HepaTx Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Argonautic Ventures Venture Capital Minority
Checkmate Capital Venture Capital Minority
Intbox Ventures Venture Capital Minority
QB3 Accelerator/Incubator
Angel (individual) Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

HepaTx FAQs

  • When was HepaTx founded?

    HepaTx was founded in 2015.

  • Where is HepaTx headquartered?

    HepaTx is headquartered in Palo Alto, CA.

  • What is the size of HepaTx?

    HepaTx has 3 total employees.

  • What industry is HepaTx in?

    HepaTx’s primary industry is Drug Discovery.

  • Is HepaTx a private or public company?

    HepaTx is a Private company.

  • What is HepaTx’s current revenue?

    The current revenue for HepaTx is .

  • How much funding has HepaTx raised over time?

    HepaTx has raised $6.96M.

  • Who are HepaTx’s investors?

    Argonautic Ventures, Checkmate Capital, Intbox Ventures, QB3, and are 5 of 15 investors who have invested in HepaTx.

  • Who are HepaTx’s competitors?

    Cellaion, LyGenesis, and Surrozen are competitors of HepaTx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process